Lertxundi U, et al. – The present study sought to determine whether the safety signal of impulse control disorders (ICDs) associated with aripiprazole detected by the US Food and Drug Administration (FDA) is replicated in the European pharmacovigilance database (EudraVigilance). The analysis of the data contained in EudraVigilance confirmed the safety signal identified last year by the FDA. The findings suggested that the association showed the strongest for the intramuscular depot formulation of aripiprazole.